# A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

> **NCT05024097** · PHASE2 · RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 43 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Etrumadenant (AB928)
- **RADIATION:** Radiation therapy
- **DRUG:** FOLFOX regimen
- **DRUG:** Zimberelimab (AB122)

## Key facts

- **NCT ID:** NCT05024097
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-31
- **Primary completion:** 2026-12
- **Final completion:** 2030-12
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05024097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05024097, "A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05024097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*